Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | TSHR | P16473 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 2/20 | 0.43 |
| ▸ | CA9 | Q16790 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.41 |
| ▸ | CAPN1 | P07384 | 8/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4714541 | 0.81 | SMN1; SMN2 (0.55) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL6717087 | 0.74 | TSHR (0.43) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL6719215 | 0.74 | TSHR (0.41) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL4715831 | 0.73 | TSHR (0.60) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL1856431 | 0.72 | SMN1; SMN2 (0.50) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL1856043 | 0.70 | SMN1; SMN2 (0.56) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL4714622 | 0.70 | TSHR (0.56) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL5048888 | 0.70 | SMN1; SMN2 (0.53) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL6719223 | 0.69 | SMN1; SMN2 (0.49) | SMN1; SMN2MEN1TSHRHTTKMT2A | |
| SCHEMBL4715815 | 0.68 | KMT2A (0.71) | SMN1; SMN2MEN1TSHRHTTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | LABORATOIRES SERONO SA (CH) | 2009-01-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090018169-A1 | Sulfonamide Derivatives for the Treatment of Bacterial Infections | STS, TST, SULT1A1 | SMN1; SMN2 2147/4885MEN1 2947/4885TSHR 1632/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.